The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer
Open accessAbstract
Purpose: Active surveillance (AS) is an option for the initial management of early-stage prostate cancer. Current risk stratification schema identify patients with low-risk disease who are presumed to be most suitable for AS. However, some men with higher risk disease also elect AS; outcomes for such men have not been widely reported. Patients and Methods: Men managed with AS at University of California, San Francisco, were classified as low- or intermediate-risk based on serum prostate-specific antigen (PSA), Gleason grade, extent of biopsy involvement, and T stage. Clinical and demographic characteristics, and progression in terms of Gleason score, PSA kinetics, and active treatment were compared between men with low- and intermediate-risk tumors. Results: Compared to men with low-risk tumors, those with intermediate-risk tumors were older (mean, 64.9 v 62.3 years) with higher mean PSA values (10.9 v 5.1 ng/mL), and more tumor involvement (mean, 20.4% v 15.3% positive biopsy cores; all P < .01). Within 4 years of the first positive biopsy, the clinical risk group did not differ in terms of the proportions experiencing progression-free survival, (low [54%] v intermediate [61%]; log-rank P = .22) or the proportions who underwent active treatment (low [30%] v intermediate [35%]; log-rank P = .88). Among men undergoing surgery, none were node positive and none had biochemical recurrence within 3 years. Conclusion: Selected men with intermediate-risk features be appropriate candidates for AS, and are not necessarily more likely to progress. AS for these men may provide an opportunity to further reduce overtreatment of disease that is unlikely to progress to advanced cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Klotz, L., Zhang, L., Lam, A., Nam, R., Mamedov, A., & Loblaw, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2180 · Cited by 1,074
COOPERBERG, M. R., PASTA, D. J., ELKIN, E. P., LITWIN, M. S., LATINI, D. M., Du CHANE, J., & CARROLL, P. R. (2005) · Journal of Urology · doi:10.1097/01.ju.0000158155.33890.e7 · Cited by 772
Self-citationPepe, M. S., Feng, Z., Janes, H., Bossuyt, P. M., & Potter, J. D. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn326 · Cited by 717
Nam, R. K., Saskin, R., Lee, Y., Liu, Y., Law, C., Klotz, L. H., Loblaw, D. A., Trachtenberg, J., Stanimirovic, A., Simor, A. E., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2012.11.015 · Cited by 592
Rethinking Screening for Breast Cancer and Prostate Cancer
Esserman, L. (2009) · JAMA · doi:10.1001/jama.2009.1498 · Cited by 516
Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment
Cooperberg, M. R., Broering, J. M., Kantoff, P. W., & Carroll, P. R. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.03.135 · Cited by 442
Self-citationOutcomes of Localized Prostate Cancer Following Conservative Management
Lu-Yao, G. L. (2009) · JAMA · doi:10.1001/jama.2009.1348 · Cited by 430
Active surveillance for the management of prostate cancer in a contemporary cohort
Dall'Era, M. A., Konety, B. R., Cowan, J. E., Shinohara, K., Stauf, F., Cooperberg, M. R., Meng, M. V., Kane, C. J., Perez, N., Master, V. A., et al. (2008) · Cancer · doi:10.1002/cncr.23502 · Cited by 404
Self-citation
Cited by
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy
McKiernan, J., Donovan, M. J., O’Neill, V., Bentink, S., Noerholm, M., Belzer, S., Skog, J., Kattan, M. W., Partin, A., Andriole, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0097 · Cited by 674
Self-citationKlein, E. A., Cooperberg, M. R., Magi-Galluzzi, C., Simko, J. P., Falzarano, S. M., Maddala, T., Chan, J. M., Li, J., Cowan, J. E., Tsiatis, A. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.004 · Cited by 659
Self-citationActive Surveillance for Prostate Cancer: A Systematic Review of the Literature
Dall’Era, M. A., Albertsen, P. C., Bangma, C., Carroll, P. R., Carter, H. B., Cooperberg, M. R., Freedland, S. J., Klotz, L. H., Parker, C., & Soloway, M. S. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.072 · Cited by 602
Self-citationPokorny, M. R., de Rooij, M., Duncan, E., Schröder, F. H., Parkinson, R., Barentsz, J. O., & Thompson, L. C. (2014) · European Urology · doi:10.1016/j.eururo.2014.03.002 · Cited by 503
Cooperberg, M. R., Simko, J. P., Cowan, J. E., Reid, J. E., Djalilvand, A., Bhatnagar, S., Gutin, A., Lanchbury, J. S., Swanson, G. P., Stone, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4396 · Cited by 351
Self-citation
Metadata
- Authors
- Cooperberg, M. R., Cowan, J. E., Hilton, J. F., Reese, A. C., Zaid, H. B., Porten, S. P., Shinohara, K., Meng, M. V., Greene, K. L., & Carroll, P. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-01-10
- Volume
- 29
- Issue
- 2
- Pages
- 228-234
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2141198296
- Cited by
- 283
- References
- 24
- FWCI
- 17.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.2010.31.4252
- The paper
- Cooperberg, M. R., Cowan, J. E., Hilton, J. F., Reese, A. C., Zaid, H. B., Porten, S. P., Shinohara, K., Meng, M. V., Greene, K. L., & Carroll, P. R. (2011). Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.31.4252
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.